Phase I/II, Open-Label Trial of Safety and Immunogenicity of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Human Immunodeficiency Virus-Infected Adolescents
- 1 May 2010
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 29 (5) , 391-396
Abstract
Background: Quadrivalent meningococcal polysaccharide conjugate vaccine (MCV4) is routinely recommended for healthy youth in the United States, but there are no data about its use in HIV-infected people. Methods: P1065 is a Phase I/II trial of MCV4 safety and immunogenicity in HIV-infected children and youth performed at 27 US sites of the IMPAACT network. All youth (11–24 years old) received 1 dose of open-label MCV4 at entry. Standardized questionnaires were used to evaluate safety. Baseline protective immunity was defined as rabbit serum bactericidal antibody (rSBA) titer ≥1:128. Immunogenic response was defined as a ≥4-fold rise in rSBA against each meningococcal serogroup. Multivariable logistic regression analysis was used to evaluate the association of demographic and clinical characteristics on immunogenic response to serogroup C. Results: Among 319 subjects who received MCV4, 10 (3.1%) reported immediate adverse events which were local and mild, and 7 (2.2%) experienced Grade ≥3 adverse events, unrelated to vaccine. The 305 subjects with serologic data had a median age of 17 years and were 59% male, 50% Black, and 38% Latino. Subjects were stratified by entry CD4%: 12%, CD4 <15%; 40%, 15% to 24%; and 48%, ≥25%. Baseline protective immunity varied by serogroup: A, 41%; C, 11%; W-135, 15%; Y, 35% The immunogenic response rates to serogroups A, C, W-135, and Y were 68%, 52%, 73%, and 63%, respectively. In multivariable logistic regression models, lower entry CD4%, higher entry viral load, and CDC Class B/C diagnosis were associated with significantly lower odds of response to serogroup C. Conclusion: Many HIV-infected youth naturally acquire meningococcal immunity. MCV4 is safe and immunogenic in HIV-infected youth, but response rates are lower than in healthy youth, particularly for those with more advanced HIV clinical, immunologic, and virologic status.Keywords
This publication has 24 references indexed in Scilit:
- Vaccination in the Immunocompromised ChildThe Pediatric Infectious Disease Journal, 2009
- Disease Susceptibility to ST11 Complex Meningococci Bearing Serogroup C or W135 Polysaccharide Capsules, North America1Emerging Infectious Diseases, 2004
- Immunogenicity and efficacy of childhood vaccines in HIV-1-infected childrenThe Lancet Infectious Diseases, 2004
- Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination eraVaccine, 2003
- Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infectionThe Pediatric Infectious Disease Journal, 2002
- Nucleoside‐Analogue Reverse‐Transcriptase Inhibitors Plus Nevirapine, Nelfinavir, or Ritonavir for Pretreated Children Infected with Human Immunodeficiency Virus Type 1Clinical Infectious Diseases, 2002
- Development of natural immunity to Neisseria meningitidisVaccine, 2001
- Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the United Kingdom: Reevaluation of Correlates of ProtectionInfection and Immunity, 2001
- Standardisation and Validation of Serological Assays for the Evaluation of Immune Responses to Neisseria meningitidis Serogroup A and C VaccinesBiologicals, 2000
- Persistence of Antibody Responses to Haemophilus influenzae Type b Polysaccharide Conjugate Vaccine in Children with Vertically Acquired Human Immunodeficiency Virus InfectionThe Pediatric Infectious Disease Journal, 1996